
News|Articles|November 15, 2012
Testimony: FDA Commissioner says FDA has limited authority over compounding pharmacies to prevent meningitis outbreak
FDA Commissioner Margaret Hamburg was asked if the fungal meningitis outbreak could have been prevented by FDA during a 4-hour hearing Nov. 14 headed by the chairman of the House Energy and Commerce oversight subcommittee. Her answer was that FDA had limited authority because the New England Compounding Center (NECC), Framingham, Mass., was a ?compounding pharmacy,? which is regulated by the state Board of Pharmacy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
CGM prescribed by primary care lowers A1C and acute care use in diabetes patients
3
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























